Merck & Co. (MRK)
(Delayed Data from NYSE)
$104.23 USD
+0.25 (0.24%)
Updated Oct 28, 2024 04:02 PM ET
After-Market: $104.26 +0.03 (0.03%) 6:54 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$104.23 USD
+0.25 (0.24%)
Updated Oct 28, 2024 04:02 PM ET
After-Market: $104.26 +0.03 (0.03%) 6:54 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Zacks News
Corcept (CORT) Down on Q2 Earnings Miss, Revenues Rise Y/Y
by Zacks Equity Research
Corcept's (CORT) earnings miss estimates in second-quarter 2022 while revenues beat the same. Shares down.
Syneos Health (SYNH) Q2 Earnings Top Estimates, Cuts '22 View
by Zacks Equity Research
Syneos Health (SYNH) posts better-than-expected earnings in the second quarter and robust results across the Clinical Solutions and Commercial Solutions businesses.
Bruker (BRKR) Q2 Earnings Match Estimates, '22 Sales View Down
by Zacks Equity Research
Robust performance across the BSI and BEST segments drove Bruker's (BRKR) second-quarter top line.
Mirati (MRTX) Q2 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Mirati Therapeutics' (MRTX) Q2 earnings and sales beat the mark. The company plans to start early-stage clinical studies for a SOS1 inhibitor by year-end.
Tandem Diabetes (TNDM) Q2 Earnings Miss, Sales View Cut
by Zacks Equity Research
Factoring the pandemic and competitive pressure as well as the evolving economic environment, including inflation and the threat of recession, Tandem Diabetes (TNDM) cuts its full-year guidance.
CVS Health (CVS) Q2 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
CVS Health (CVS) posts better-than-expected results in Q2, with robust performances across all operating segments driving the top line.
Exact Sciences (EXAS) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Exact Sciences (EXAS) posts better-than-expected earnings and revenues in Q2 with robust performances across the Screening and Precision Oncology segments.
Charles River (CRL) Q2 Earnings Top Estimates, 2022 View Cut
by Zacks Equity Research
Revenue decline in the CDMO business drag Charles River's (CRL) Manufacturing Solutions revenues down.
STERIS (STE) Q1 Earnings Match Estimates, EPS View Down
by Zacks Equity Research
STERIS' (STE) revenues at AST improve driven by increased demand from medical device and biopharma customers.
Henry Schein (HSIC) Q2 Earnings Top Estimates, '22 EPS View Up
by Zacks Equity Research
Henry Schein (HSIC) reports better-than-expected Q2 earnings with impressive sales growth across the Medical and Technology and Value-added Services segments.
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Looking for a Growth Stock? 3 Reasons Why Merck (MRK) is a Solid Choice
by Zacks Equity Research
Merck (MRK) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Merck (MRK) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Merck (MRK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The Zacks Analyst Blog Highlights GSK, Merck, Pfizer, Sanofi and AstraZeneca
by Zacks Equity Research
GSK, Merck, Pfizer, Sanofi and AstraZeneca are part of Zacks top Analyst Blog.
Seagen's (SGEN) Earnings & Revenues Surpass Estimates in Q2
by Zacks Equity Research
Seagen (SGEN) reports a narrower-than-expected loss in the second quarter of 2022 while its revenues beat estimates.
Pharma Stock Roundup: MRK, PFE, SNY Q2 Earnings & Sales Beat, GSK Results Mixed
by Kinjel Shah
GSK plc (GSK), Merck (MRK), Pfizer (PFE), Sanofi (SNY) and AstraZeneca (AZN) announce second-quarter results
AstraZeneca (AZN) Beats on Q2 Earnings, Ups Sales Growth View
by Zacks Equity Research
AstraZeneca's (AZN) second-quarter results reflect a beat on both counts (revenues and earnings). AZN raises its 2022 sales growth guidance, keeping its profit forecast unchanged.
Merck (MRK) Q2 Earnings & Revenues Top, COVID Drug Helps Sales
by Zacks Equity Research
Merck (MRK) beats on Q2 estimates for earnings and sales. The company continues to see robust growth in COVID drug sales and Keytruda and Gardasil sales.
Alkermes' (ALKS) Earnings & Revenues Surpass Estimates in Q2
by Zacks Equity Research
Alkermes (ALKS) beat estimates for both earnings and sales in the second quarter of 2022. The company narrows sales guidance for Vivitrol and Aristada. Stock down.
Merck (MRK) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 11.98% and 5.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Should Invesco Dow Jones Industrial Average Dividend ETF (DJD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DJD
Drug, Biotech Stocks' Q2 Earnings on Jul 28: MRK, PFE & More
by Zacks Equity Research
Let's analyze how the five pharma/drug/biotech companies are placed before the quarterly earnings release on Jul 28.
Merck (MRK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, and COVID-19 antiviral pill, molnupiravir when the company reports Q2 earnings.
The Zacks Analyst Blog Highlights J&J, Novartis, GSK, Merck and AbbVie
by Zacks Equity Research
J&J, Novartis, GSK, Merck and AbbVie are included in this Analyst Blog.
Merck Q2 Preview: Double-Digit Earnings Growth in Store?
by Derek Lewis
Year-to-date, Merck shares are well in the green, increasing nearly 20% in value and easily outperforming its Zacks Industry.